atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 13, 2024 08:00 ET
|
atai Life Sciences
Q3 2024 earnings
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 15, 2024 08:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of...
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024 07:10 ET
|
atai Life Sciences
atai Reports Q2 2024 Financial Results and Corporate Updates
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024 07:00 ET
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024 07:00 ET
|
atai Life Sciences
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference in August 2024
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 26, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
June 20, 2024 07:00 ET
|
atai Life Sciences
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of...
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 23, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...